Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
HTFL affiliate filed a Form 144 to report proposed resale of 22,562 shares of Common Stock tied to a stock option exercise dated 06/25/2024. The filing also lists three dispositions by John C.M. Farquhar: 22,562 shares on 02/10/2026, 12,837 shares on 03/10/2026, and 9,725 shares on 03/18/2026, with proceeds shown for each transaction.
Heartflow, Inc. Chief Medical Officer Campbell Rogers exercised stock options and sold shares of common stock. On April 1, 2026, he exercised options covering 67,017 shares of common stock at exercise prices of $2.22 and $8.33 per share and received the same number of common shares.
That day, he sold 64,533 shares of common stock at a weighted average price of $24.64 per share in open-market transactions, as part of a Rule 10b5-1 Trading Plan adopted on September 12, 2025. Following these transactions, he holds 81,002 shares directly, along with indirect holdings through several trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust.
HTFL notice of proposed sale under Rule 144 describing planned and recent disposals of Common Stock by named holders and options-related issuances.
The filing lists planned sales tied to prior stock option exercises (12/27/2019: 13,047 shares; 02/17/2021: 3,867 shares; 07/31/2025: 4 shares; 07/10/2023 grant exercised 47,615 shares) and shows actual sales in the past three months by related holders on 02/12/2026 and 03/19/2026 (examples: 16,918 and 47,615 shares with dollar proceeds reported).
Heartflow, Inc. ownership disclosure: HealthCor Partners Management, L.P. reports beneficial ownership of 2,082,014 shares of common stock, representing 2.4% of the class. The filing breaks this down as HealthCor Partners Fund, L.P. 1,248,939 shares (1.5%) and HealthCor Partners Fund II, L.P. 833,075 shares (1.0%). The filing notes a distribution by HCPCIV 1, LLC of 4,615,542 shares on March 24, 2026.
Heartflow, Inc. director Jeffrey C. Lightcap reported an internal restructuring of his share ownership. On March 24, 2026, HCPCIV 1, LLC made a pro rata in-kind distribution of Heartflow common stock to its members, including 206,261 shares allocable to Mr. Lightcap based on his indirect interest. Following this distribution and the dissolution of HCPCIV, these shares are now held directly by Mr. Lightcap, with 246,261 shares shown as directly owned after the transaction. He is also a controlling member of HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P., which report 833,075 and 1,248,939 shares held indirectly, respectively, although he disclaims beneficial ownership beyond his pecuniary interest.
Heartflow, Inc. insider HealthCor Partners Management LP reported a restructuring-type transaction involving 4,615,542 shares of Heartflow common stock. On March 24, 2026, these shares, held indirectly through HCPCIV I, LLC, were distributed to fund investors, and the reporting person’s indirect holdings in this block dropped to zero. This was classified as an “other” transaction rather than an open-market purchase or sale.
Heartflow, Inc. Chief Medical Officer Campbell Rogers exercised stock options and sold shares of common stock. He exercised options covering 67,017 shares of common stock at an exercise price of $2.22 per share, then sold 64,533 shares at a weighted average price of $25.6928 per share in trades ranging from $25.00 to $28.00.
The option exercise and related sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025. Following these transactions, Rogers holds 78,518 shares of Heartflow common stock directly, along with additional indirect holdings through several trusts, including 22,615 shares held by the Campbell Rogers 2019 Irrevocable Trust.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar sold 9,725 shares of Common Stock in an open-market transaction at $25.00 per share on March 18, 2026. After this sale, he directly holds 571,725 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, indicating it was scheduled in advance rather than timed discretionarily.
HTFL Form 144 filings report proposed sales of Common Stock by affiliated holders. Campbell D. Rogers reported 48,235 shares with proceeds shown as $1,181,198.43 and Campbell & Sarah Rogers Trustees reported 16,918 shares with proceeds shown as $414,287.24, both dated 02/12/2026.
Heartflow, Inc. provides an AI-powered software platform to non‑invasively diagnose and manage coronary artery disease using coronary CT angiography. As of December 31, 2025, its Heartflow Platform has been used in more than 600,000 patients and deployed at over 1,465 U.S. accounts.
The company’s flagship Heartflow FFRCT Analysis, which represented 98% of revenue as of December 31, 2025, estimates vessel-specific blood flow and lesion significance, while Heartflow Plaque Analysis quantifies and characterizes coronary plaque. A workflow tool, Heartflow RoadMap Analysis, is integrated into accounts, and Heartflow PCI Navigator is expected to launch in the second quarter of 2026.
Heartflow emphasizes extensive clinical validation, citing over 200 studies and large randomized trials like PRECISE and FORECAST, and benefits from strong guideline support and Category I CPT codes for FFRCT (75580) and Plaque Analysis (75577). Its growth strategy focuses on expanding account adoption, increasing utilization within existing sites, broadening Plaque Analysis coverage, and investing in additional clinical evidence and product innovation.